DGAP-Adhoc: 4SC reports on positive results from a clinical phase I trial with cancer drug candidate 4SC-201

4SC AG / Miscellaneous

21.10.2008 

Release of a Adhoc News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------

Planegg-Martinsried, Germany, 21 October 2008 - The Martinsried-based drug
discovery and development company 4SC AG (Frankfurt, Prime Standard: VSC)
announced today that the clinical phase I trial with the drug candidate
4SC-201, an innovative substance from the histone deacetylase (HDAC) class
of inhibitors, for the treatment of cancer has progressed very well.

The first available study results prove that 4SC-201 can be administered
safely, is highly tolerable and shows a particularly advantageous
pharmacological profile. At advanced stages of this study (i.e. 4SC-201
given orally once daily at 600 mg and 800 mg), different cancers were seen
to stabilise in several patients. In some of these cases, with an optional,
prolonged treatment with 4SC-201 that went beyond the main therapy plan, to
date the treatment period has already reached up to six months.

In this trial, being conducted at the Royal Marsden Hospital in Sutton near
London, under the direction of Professor Dr. J. S. de Bono, patients who
suffer from a progressed solid tumour disease or from malignant lymphomas
can be accepted. They have received at least one previous standard therapy,
or no standard therapy exists for them. To date, a total of 17 evaluable
patients have been included in the trial.

The conclusion, and with it the final results of the trial, are expected
shortly. It is on this basis that the enterprise plans to begin with
different efficacy studies during clinical phase II tests on different
tumour diseases in the coming year.

End of ad hoc notification


About 4SC-201:
4SC-201 is an innovative substance from the histone deacetylase (HDAC)
class of inhibitors. It concerns one of the drug candidates, which 4SC AG
took over in July of this year from Nycomed, with the former designation
BYK408740. Compared with other cancer drugs, which also block the HDAC
enzyme, this candidate showed a particularly good pharmacokinetic profile
upon oral application in previous test series. In addition, a very good
safety profile and very good efficacy were observed with respect to its
broad anti-tumour activity in preclinical models.

About 4SC:
4SC AG (ISIN DE0005753818) has been listed in the Prime Standard of
Frankfurt Stock Exchange since 15 December 2005. Founded in 1997 and now
with a staff of 77 employees, the company develops novel drug candidates
against inflammatory diseases and cancer. 4SC AG utilises its patent
protected platform, to create a sustainable project pipeline of drug
candidates, which are to be developed up to clinical efficacy in early
clinical phases ('proof of concept') and subsequently partnered with the
pharmaceutical industry in return for advance and milestone payments as
well as royalties. There are currently eight projects in the development
pipeline and a rich pool of further discovery projects. Clinical phase IIa
for the first project for the treatment of rheumatoid arthritis has already
successfully been completed. An additional project for the treatment of
various cancers is currently completing a clinical phase I trial. Further
projects are in advanced pre-clinical stages.
Further information is to be found at www.4sc.com. 

Legal Note
This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject
to risks and uncertainties, many of which are beyond our control. Actual
results could differ materially, depending on a number of factors.




For more information please contact us!

Bettina von Klitzing 
Manager Investor Relations und Public Relations
4SC AG 
Tel.: +49 (0) 89 70 07 63 - 0 
Bettina.von.klitzing@4sc.com 







DGAP 21.10.2008 
---------------------------------------------------------------------------
Language:     English
Issuer:       4SC AG
              Am Klopferspitz 19a
              82152 Martinsried
              Deutschland
Phone:        +49 (0)89 7007 63-0
Fax:          +49 (0)89 7007 63-29
E-mail:       public@4sc.com
Internet:     www.4sc.de
ISIN:         DE0005753818
WKN:          575381
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, München, Stuttgart
End of News                                     DGAP News-Service
---------------------------------------------------------------------------